{
  "docId": "019dd923-622b-71dc-a6d9-a17d7f297d05",
  "docSlug": "f72bb77d31b3",
  "documentTitle": "Alexion Pharmaceuticals, Inc. (ALXN)",
  "authorId": "02_Elliott_Management",
  "authorName": "Elliott",
  "documentKindSlug": "shareholder-letter",
  "documentKindLabel": "Shareholder letter",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2020-05-12 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.7072243,
  "pageNumber": 1,
  "pageCount": 10,
  "prevPage": null,
  "nextPage": 2,
  "slideType": "executive_summary",
  "function": "front_matter",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "This is a formal shareholder letter from Elliott Advisors to Alexion Pharmaceuticals, dated May 12, 2020.",
  "elementsJson": [
    "logo_grid",
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": "https://imgproxy.kitesheet.com/70mvC6eSzDBP4k9Fbw76S0B3lUtlIaN3PQ6BxgV2mWA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNzJiYjc3ZDMxYjMvcDAwMS5wbmc",
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-a17d7f297d05/1",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-a17d7f297d05",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-a17d7f297d05.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-a17d7f297d05#slide-1",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "the best approach for the Company and its stakeholders is the immediate exploration of a sale, which, as explained below, would create significant upside for shareholders while creating a more stable footing for all those with a vested interest in Alexion's future – including its patients.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5ba-cd07a5f0d236",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.35,
        "y": 0.05
      },
      "kind": "other",
      "text": "ELLIOTT ADVISORS (UK) LIMITED",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41ba8138-291d-4eba-9539-8633d629cc3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "A detailed review... led us to conclude last year that the best approach for the Company and its stakeholders is the immediate exploration of a sale.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31ab8a0a-7a2f-45d8-91ec-d5a7e1973d7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "However, the Portola announcement's profoundly negative impact on shareholder value – erasing approximately $1.7 billion from the Company's market capitalization in a single day – has led us to conclude that a broader public discussion is necessary.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c5b2256-bfc8-4714-8983-0138c6a1863b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "On behalf of funds advised by Elliott... we are writing to share with you our latest perspectives on the Company's future.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83248052-056a-4e8b-bfcf-9c9862f0309c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.1,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Daily change in market capitalization, adjusted for iShares NASDAQ Biotechnology Index move",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc1502cd-fd7f-43c3-9f73-a4a9ab9005df",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis: Activist defense (for management)",
      "slug": "activist-defense",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "48c04945-a42b-47a0-b6ba-ea0da172d258",
      "evidence": "However, the Portola announcement's profoundly negative impact on shareholder value – erasing approximately $1.7 billion from the Company's market capitalization in a single day – has led us to concl",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": "https://imgproxy.kitesheet.com/9MOsoL-E0XTbhUqkSfmbmj5xWXxsY4HjHb846hxgOLg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNzJiYjc3ZDMxYjMvcDAwMS5qcGc",
  "thumbSrc": "https://imgproxy.kitesheet.com/NQr-7a6HMr1ounBsAxDicMXYHTdCeSUJ3ddlKBX39Wg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNzJiYjc3ZDMxYjMvcDAwMS5wbmc",
  "thumbSrcAlt": "https://imgproxy.kitesheet.com/tpa4qk4ShjpW3v9TmmcNojj_Iv3KUcW_iE5VH02V-Rk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNzJiYjc3ZDMxYjMvcDAwMS5qcGc"
}